Research on the Potential Mechanism of Gentiopicroside Against Gastric Cancer Based on Network Pharmacology

Yanxia Huang,1,2,* Jiatong Lin,1,3,* Weimin Yi,1,2,* Qinghua Liu,1,4 Linhui Cao,1,2 Yongcong Yan,1,4 Anqi Fu,5 Tingxuan Huang,5 Yingcheng Lyu,1,3 Qihui Huang,1,2 Jie Wang1,4 1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China; 2Department of Traditional Chinese Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People’s Republic of China; 3Department of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China; 4Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People’s Republic of China; 5Sun Yat-Sen University Zhongshan School of Medicine, Guangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jie WangDepartment of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Yanjiang West Road 107#, Guangzhou 510120, People’s Republic of ChinaEmail jiewsysu@163.comQihui HuangDepartment of Traditional Chinese Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Yanjiang West Road 107#, Guangzhou 510120, People’s Republic of ChinaEmail hqhui84181833@sina.comBackground: Gastric cancer was still one of the commonly diagnosed cancer types and the third-most common cause of cancer-related death in the world. Gentiopicroside, which is extracted from the Gentianella acuta, is commonly used in both traditional treatment and modern clinical care; therefore, its anticancer effects have been attracted more attention. However, the systematic analysis of action mechanism of Gentiopicroside on gastric cancer (GC) has not yet been carried out.Aim: A network pharmacology-based strategy combined with molecular docking studies and in vitro validation was employed to investigate potenti